Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 478

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 8
Chunk 478
---
 131,784 Proceeds from milestone payment from gain on sale of oncology business200,000 — — Payments associated with license agreement— (17,500)— Purchases of property and equipment(1,685)(999)(4,881)Proceeds from sale of equipment40 1,325 964 Net cash provided by investing activities363,441 239,575 243,261 Financing activitiesPayments on financing lease obligations— — (331)Net proceeds from stock option exercises and employee stock purchase plan14,442 5,433 2,681 Net cash provided by financing activities14,442 5,433 2,350 Net change in cash and cash equivalents(11,958)(51,054)(63,867)Cash and cash equivalents at beginning of the period88,205 139,259 203,126 Cash and cash equivalents at end of the period$76,247 $88,205 $139,259 Supplemental disclosure of non-cash investing and financing transactions:Additions to property and equipment in accounts payable and accrued expenses$317 $55 $158 Net cash taxes paid$43,150 $1,569 $— 

See accompanying Notes to Consolidated Financial Statements.

F-8